TY - JOUR
T1 - Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia
AU - Del Principe, Maria Ilaria
AU - Dal Bo, Michele
AU - Bittolo, Tamara
AU - Buccisano, Francesco
AU - Rossi, Francesca Maria
AU - Zucchetto, Antonella
AU - Rossi, Davide
AU - Bomben, Riccardo
AU - Maurillo, Luca
AU - Cefalo, Mariagiovanna
AU - De Santis, Giovanna
AU - Venditti, Adriano
AU - Gaidano, Gianluca
AU - Amadori, Sergio
AU - de Fabritiis, Paolo
AU - Gattei, Valter
AU - Del Poeta, Giovanni
PY - 2016
Y1 - 2016
N2 - In chronic lymphocytic leukemia the balance between the pro-apoptotic and anti-apoptotic members of the bcl-2 family is involved in the pathogenesis, chemorefractoriness and clinical outcome. Moreover, the recently proposed anti-bcl-2 molecules, such as ABT-199, have emphasized the potential role of of bcl-2 family proteins in the context of target therapies. We investigated bax/bcl-2 ratio by flow cytometry in 502 patients and identified a cut off of 1.50 to correlate bax/bcl-2 ratio with well-established clinical and biological prognosticators. Bax/bcl-2 was 1.50 or over in 263 patients (52%) with chronic lymphocytic leukemia. Higher bax/bcl-2 was associated with low Rai stage, lymphocyte doubling time over 12 months, beta-2 microglobulin less than 2.2 mg/dL, soluble CD23 less than 70 U/mL and a low risk cytogenetic profile (P
AB - In chronic lymphocytic leukemia the balance between the pro-apoptotic and anti-apoptotic members of the bcl-2 family is involved in the pathogenesis, chemorefractoriness and clinical outcome. Moreover, the recently proposed anti-bcl-2 molecules, such as ABT-199, have emphasized the potential role of of bcl-2 family proteins in the context of target therapies. We investigated bax/bcl-2 ratio by flow cytometry in 502 patients and identified a cut off of 1.50 to correlate bax/bcl-2 ratio with well-established clinical and biological prognosticators. Bax/bcl-2 was 1.50 or over in 263 patients (52%) with chronic lymphocytic leukemia. Higher bax/bcl-2 was associated with low Rai stage, lymphocyte doubling time over 12 months, beta-2 microglobulin less than 2.2 mg/dL, soluble CD23 less than 70 U/mL and a low risk cytogenetic profile (P
UR - http://www.scopus.com/inward/record.url?scp=84952944999&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84952944999&partnerID=8YFLogxK
U2 - 10.3324/haematol.2015.131854
DO - 10.3324/haematol.2015.131854
M3 - Article
AN - SCOPUS:84952944999
VL - 101
SP - 77
EP - 85
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 1
ER -